|
Market Cap (25-Jun) $19,510,578 (1,113th) |
Close (30-Jun) $0.049 |
Volume (30-Jun) 1,094,468 |
Shortsold (12-Jul) 1 (0.00%) (672nd) |
|
52w High $0.000 |
52w Low $0.000 |
P/E 20.45 |
EPS -0.02 |
PXS released this announcement to the ASX on 7 April 2021, 9:32. The announcement is not marked as price sensitive, and is 15 page(s) in length and 193.49kb in size.
You can view all announcements from PXS and see how they appear on a price chart on the announcements page.
At the date of this announcement, PXS was 0.057% short sold according to ASIC data. It was ranked the 467th most shorted stock on the ASX. It remains ranked 672nd as of the latest reported data (12 July 2023).
| Other Recent Announcements from PXS | |
|---|---|
| Investor presentation | 24 May 2023, 8:21 |
| PXS Announces Encouraging Results from Phase 1c Scar Study | 23 May 2023, 16:32 |
| Trading Halt | 22 May 2023, 8:56 |
| Appendix 2A - Exercise of Employee Options | 7 April 2021, 9:32 |
| Clinical Trial of Treatment to Prevent Wound and Burns Scars | 31 March 2021, 11:20 |
| US Commercial Launch of Bronchitol | 19 March 2021, 8:20 |
| First Patient Enrolled - Clinical Trial for Cancer Treatment | 22 February 2021, 9:50 |
You must be logged in to post a reply.
Pharmaxis Ltd 